H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.

H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating

On March 5, 2026, H.C. Wainwright raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $6 from $4 previously and maintained a Buy rating following the company’s fourth-quarter report. H.C. Wainwright increased the probability of success for pilavapadin to 30% from 15% and said the program could attract an “important partnership” as Lexicon’s clinical and regulatory progress helps de-risk the Phase 3-ready asset.

On March 5, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported fourth-quarter EPS of (4c) compared with consensus estimates of (7c). Revenue totaled $5.5 million versus the consensus of $3.14 million. As of December 31, 2025, the company held $125.2 million in cash, investments, and restricted cash, down from $238.0 million in cash and investments as of December 31, 2024. Chief Executive Officer Mike Exton said that the fourth quarter capped “an incredible year” for the company as it advanced pipeline programs, established development and commercialization agreements with global collaborators, and worked with regulators while maintaining operational efficiency. Mike Exton has added that the company entered 2026 with momentum and multiple upcoming catalysts.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat human disease.

While we acknowledge the potential of LXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LXRX and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.